Recombinant alpha‐2B interferon treatment for childhood t‐lymphoblastic disease in relapse. A pediatric oncology group phase II study

Stephen J. Lauer, Judith Ochs, Bradley H Pollock, George R. Buchanan

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background. Children with chemotherapy refractory T‐cell lymphoblastic leukemia/lymphoma were given alpha‐interferon (α‐IFN) to evaluate the efficacy and toxicity of this biologic response modifier. Methods. Twenty children with T‐cell acute lymphoblastic leukemia (T‐cell ALL) in marrow relapse and one patient with mediastinal recurrence of T‐cell non‐Hodgkin's lymphoma (T‐cell NHL) were enrolled. All patients had failed at least two previous multiagent drug trials. Recombinant α‐IFN was given at 30 million U/M2/dose intravenously or subcutaneously for 10 doses over 14 days, followed by 3 doses per week until disease progression occurred. Results.. One child had a complete response (<5% blasts) and three patients a partial response (5‐25% blasts) in their bone marrow. All patients eventually showed signs of progressive disease. Significant toxicities included cardiac hypofunction in two patients and profound lethargy in two patients. Conclusions. α‐IFN is tolerated in children with Tcell ALL and T‐cell NHL and has activity against chemotherapy resistant disease.

Original languageEnglish (US)
Pages (from-to)197-202
Number of pages6
JournalCancer
Volume74
Issue number1
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Interferons
Pediatrics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Non-Hodgkin's Lymphoma
Therapeutics
Bone Marrow
Drug Therapy
Lethargy
Disease Progression
Pharmaceutical Preparations

Keywords

  • alpha‐interferon
  • childhood T‐cell lymphoblastic disease
  • relapsed T‐cell lymphoblastic disease
  • Tcell acute lymphoblastic leukemia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Recombinant alpha‐2B interferon treatment for childhood t‐lymphoblastic disease in relapse. A pediatric oncology group phase II study. / Lauer, Stephen J.; Ochs, Judith; Pollock, Bradley H; Buchanan, George R.

In: Cancer, Vol. 74, No. 1, 1994, p. 197-202.

Research output: Contribution to journalArticle

@article{adef5aac26054df28a26f0ed85b85e0c,
title = "Recombinant alpha‐2B interferon treatment for childhood t‐lymphoblastic disease in relapse. A pediatric oncology group phase II study",
abstract = "Background. Children with chemotherapy refractory T‐cell lymphoblastic leukemia/lymphoma were given alpha‐interferon (α‐IFN) to evaluate the efficacy and toxicity of this biologic response modifier. Methods. Twenty children with T‐cell acute lymphoblastic leukemia (T‐cell ALL) in marrow relapse and one patient with mediastinal recurrence of T‐cell non‐Hodgkin's lymphoma (T‐cell NHL) were enrolled. All patients had failed at least two previous multiagent drug trials. Recombinant α‐IFN was given at 30 million U/M2/dose intravenously or subcutaneously for 10 doses over 14 days, followed by 3 doses per week until disease progression occurred. Results.. One child had a complete response (<5{\%} blasts) and three patients a partial response (5‐25{\%} blasts) in their bone marrow. All patients eventually showed signs of progressive disease. Significant toxicities included cardiac hypofunction in two patients and profound lethargy in two patients. Conclusions. α‐IFN is tolerated in children with Tcell ALL and T‐cell NHL and has activity against chemotherapy resistant disease.",
keywords = "alpha‐interferon, childhood T‐cell lymphoblastic disease, relapsed T‐cell lymphoblastic disease, Tcell acute lymphoblastic leukemia",
author = "Lauer, {Stephen J.} and Judith Ochs and Pollock, {Bradley H} and Buchanan, {George R.}",
year = "1994",
doi = "10.1002/1097-0142(19940701)74:1<197::AID-CNCR2820740131>3.0.CO;2-9",
language = "English (US)",
volume = "74",
pages = "197--202",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Recombinant alpha‐2B interferon treatment for childhood t‐lymphoblastic disease in relapse. A pediatric oncology group phase II study

AU - Lauer, Stephen J.

AU - Ochs, Judith

AU - Pollock, Bradley H

AU - Buchanan, George R.

PY - 1994

Y1 - 1994

N2 - Background. Children with chemotherapy refractory T‐cell lymphoblastic leukemia/lymphoma were given alpha‐interferon (α‐IFN) to evaluate the efficacy and toxicity of this biologic response modifier. Methods. Twenty children with T‐cell acute lymphoblastic leukemia (T‐cell ALL) in marrow relapse and one patient with mediastinal recurrence of T‐cell non‐Hodgkin's lymphoma (T‐cell NHL) were enrolled. All patients had failed at least two previous multiagent drug trials. Recombinant α‐IFN was given at 30 million U/M2/dose intravenously or subcutaneously for 10 doses over 14 days, followed by 3 doses per week until disease progression occurred. Results.. One child had a complete response (<5% blasts) and three patients a partial response (5‐25% blasts) in their bone marrow. All patients eventually showed signs of progressive disease. Significant toxicities included cardiac hypofunction in two patients and profound lethargy in two patients. Conclusions. α‐IFN is tolerated in children with Tcell ALL and T‐cell NHL and has activity against chemotherapy resistant disease.

AB - Background. Children with chemotherapy refractory T‐cell lymphoblastic leukemia/lymphoma were given alpha‐interferon (α‐IFN) to evaluate the efficacy and toxicity of this biologic response modifier. Methods. Twenty children with T‐cell acute lymphoblastic leukemia (T‐cell ALL) in marrow relapse and one patient with mediastinal recurrence of T‐cell non‐Hodgkin's lymphoma (T‐cell NHL) were enrolled. All patients had failed at least two previous multiagent drug trials. Recombinant α‐IFN was given at 30 million U/M2/dose intravenously or subcutaneously for 10 doses over 14 days, followed by 3 doses per week until disease progression occurred. Results.. One child had a complete response (<5% blasts) and three patients a partial response (5‐25% blasts) in their bone marrow. All patients eventually showed signs of progressive disease. Significant toxicities included cardiac hypofunction in two patients and profound lethargy in two patients. Conclusions. α‐IFN is tolerated in children with Tcell ALL and T‐cell NHL and has activity against chemotherapy resistant disease.

KW - alpha‐interferon

KW - childhood T‐cell lymphoblastic disease

KW - relapsed T‐cell lymphoblastic disease

KW - Tcell acute lymphoblastic leukemia

UR - http://www.scopus.com/inward/record.url?scp=0028229773&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028229773&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19940701)74:1<197::AID-CNCR2820740131>3.0.CO;2-9

DO - 10.1002/1097-0142(19940701)74:1<197::AID-CNCR2820740131>3.0.CO;2-9

M3 - Article

C2 - 8004576

AN - SCOPUS:0028229773

VL - 74

SP - 197

EP - 202

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -